BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:WVE-006 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of WVE-006\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06405633-10846@assetmemo.bio
DTSTAMP:20261121T005925Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:WVE-006: Phase 1/2 readout est. (NCT06405633)
DESCRIPTION:WVE-006\, phase 1/2\, Alpha-1 Antitrypsin Deficiency.\nStudy: A
  Phase 1b/2a\, Open-label Single Ascending Doses and Multiple Ascending Do
 ses Study in Participants With Pi*ZZ AATD\nEstimated primary completion: S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/wve-00
 6#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 405633
URL:https://assetmemo.bio/drug/wve-006#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
